The involvement of IL-6 has been emphasized in certain disorders, and tocilizumab has been demonstrated to be highly efficacious in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, and Castleman’s disease [40]. Here, IL6 is linked to Castleman disease.